Genentech and Alnylam Initiate Phase III Trial for Zilebesiran to Address Uncontrolled Hypertension
Genentech, in collaboration with Alnylam, has announced the initiation of a Phase III cardiovascular outcomes trial for zilebesiran, an RNAi therap...